# Survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma

## TL;DR

The study examines survival and treatment response in patients with advanced head and neck cancer treated with checkpoint inhibitors.

## Contribution

The study provides survival data and response rates for checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma.

## Key findings

- Median overall survival was 13.1 months.
- Median progression-free survival was 4.1 months.
- Estimated 1-year overall survival was 53.9%.

## Abstract

Evaluation of survival outcomes and response rates among patients with recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC) treated with checkpoint inhibitors is of interest. Data regarding overall survival (OS), progression free survival (PFS),
response rate, PD-L1 combined positive score (CPS) was retrieved. A total of 412 patients with histo-pathologically confirmed recurrent
or metastatic HNSCC who received checkpoint inhibitor (CPI) treatment were ultimately included as members of the cohort. The median
overall survival was 13.1 months. Median PFS was 4.1 months. The estimated 1-year overall survival was 53.9% while estimated 1-year PFS
was 9.7%. Thus, the use of CPI therapies for first - or second-line treatment of recurrent or metastatic head and neck squamous cell
carcinoma is shown.